BCT Stock Overview
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
BriaCell Therapeutics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$3.09 |
| 52 Week High | CA$10.29 |
| 52 Week Low | CA$2.80 |
| Beta | 1.75 |
| 1 Month Change | -20.36% |
| 3 Month Change | -41.59% |
| 1 Year Change | -67.13% |
| 3 Year Change | -19.74% |
| 5 Year Change | -87.88% |
| Change since IPO | -96.45% |
Recent News & Updates
Shareholder Returns
| BCT | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 1.3% | 1.7% | 3.1% |
| 1Y | -67.1% | -34.7% | 8.8% |
Return vs Industry: BCT underperformed the Canadian Biotechs industry which returned -34.7% over the past year.
Return vs Market: BCT underperformed the Canadian Market which returned 8.8% over the past year.
Price Volatility
| BCT volatility | |
|---|---|
| BCT Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CA Market | 17.8% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: BCT's share price has been volatile over the past 3 months.
Volatility Over Time: BCT's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 16 | Bill Williams | briacell.com |
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.
BriaCell Therapeutics Corp. Fundamentals Summary
| BCT fundamental statistics | |
|---|---|
| Market cap | CA$49.22m |
| Earnings (TTM) | -CA$17.24m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs BCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$12.61m |
| Earnings | -US$12.61m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.79 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BCT perform over the long term?
See historical performance and comparison